Selected for the Ministry of the Environment’s “Model Project to Promote Decarbonization Across the Entire Value Chain”
~12 Companies Participate in Developing Common CO2 Emissions Calculation Rules for the Pharmaceutical Industry~
July 22, 2025
Japan Pharmaceutical Manufacturers Association
We are pleased to announce that the Carbon Neutrality Group of the Environmental Issue Committee of the Japan Pharmaceutical Manufacturers Association (hereinafter referred to as “JPMA”) has applied for and been provisionally selected for the Ministry of the Environment’s Reiwa 7 “Model Project to Promote Decarbonization Across the Entire Value Chain (Industry Associations)” program, for which applications were publicly solicited.
The following 12 member companies of the JPMA will participate in this project:
Astellas Pharma Inc., AstraZeneca K.K., Eisai Co., Ltd., KISSEI PHARMACEUTICAL CO., LTD., Sanofi K.K., SANTEN PHARMACEUTICAL CO., LTD., SHIONOGI & CO., LTD., DAIICHI SANKYO CO., LTD., CHUGAI PHARMACEUTICAL CO., LTD., NIPPON SHINYAKU Co., Ltd., TAKEDA PHARMACEUTICAL COMPANY LIMITED, and Meiji Seika Pharma Co., Ltd.
The Japan Pharmaceutical Manufacturers Association (hereinafter referred to as “JPMA”) is working in collaboration with its member companies to advance initiatives aimed at achieving carbon neutrality across the entire pharmaceutical industry.
This initiative is a support program aimed at reducing emissions across the entire value chain at the industry level, and it supports efforts to establish industry-wide guidelines for Scope 3 calculations, primary data collection, and engagement policies.
This initiative contributes to the realization of “Trust: Ensuring Ethics and Transparency to Become an Industry Trusted by Society,” one of the priority areas outlined in JPMA’s Vision for 2035 announced in February 2025.We will widely share the insights gained through this project to contribute to solving environmental challenges, such as climate change, which have a serious impact on people’s health. Through these efforts, we aim to realize a sustainable society that supports a stable supply of pharmaceuticals.